홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.0
  1. 홈
  2. /반응

Ethyl(4-piperidin-4-yl-piperazin-1-yl)-acetate → [4-(1-{2-(4-chloro-3-trifluoromethyl-benzyl)-4-oxo-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butyryl}-piperidin-4-yl)-piperazin-1-yl]-acetic acid

HRID 736957
노트
인쇄 미리보기

반응식

HRID 736957 반응식
[Cl:1][C:2]1[CH:32]=[CH:31][C:5]([CH2:6][CH:7]([CH2:11][C:12](=[O:30])[N:13]2[CH2:18][CH2:17][CH:16]([N:19]3[CH2:28][C:27]4[C:22](=[CH:23][CH:24]=[CH:25][CH:26]=4)[NH:21][C:20]3=[O:29])[CH2:15][CH2:14]2)[C:8]([OH:10])=O)=[CH:4][C:3]=1[C:33]([F:36])([F:35])[F:34].C([O:39][C:40](=[O:54])[CH2:41][N:42]1[CH2:47][CH2:46][N:45]([CH:48]2[CH2:53][CH2:52][NH:51][CH2:50][CH2:49]2)[CH2:44][CH2:43]1)C>>[Cl:1][C:2]1[CH:32]=[CH:31][C:5]([CH2:6][CH:7]([CH2:11][C:12](=[O:30])[N:13]2[CH2:18][CH2:17][CH:16]([N:19]3[CH2:28][C:27]4[C:22](=[CH:23][CH:24]=[CH:25][CH:26]=4)[NH:21][C:20]3=[O:29])[CH2:15][CH2:14]2)[C:8]([N:51]2[CH2:52][CH2:53][CH:48]([N:45]3[CH2:46][CH2:47][N:42]([CH2:41][C:40]([OH:54])=[O:39])[CH2:43][CH2:44]3)[CH2:49][CH2:50]2)=[O:10])=[CH:4][C:3]=1[C:33]([F:36])([F:34])[F:35]
참가 물질실험 절차출처 및 근거반응 노트

참가 물질

3

반응물 2

HCID 57848475Ethyl(4-piperidin-4-yl-piperazin-1-yl)-acetateHCID 685923932-(4-chloro-3-trifluoromethyl-benzyl)-4-oxo-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butanoic acid

생성물 1

HCID 57848346[4-(1-{2-(4-chloro-3-trifluoromethyl-benzyl)-4-oxo-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butyryl}-piperidin-4-yl)-piperazin-1-yl]-acetic acid

실험 절차

Prepared analogously to Example 16.4 from 105 mg (0.2 mmol) 2-(4-chloro-3-trifluoromethyl-benzyl)-4-oxo-4-[4-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidin-1-yl]-butanoic acid and 51 mg (0.2 mmol) ethyl(4-piperidin-4-yl-piperazin-1-yl)-acetate.

출처 및 근거

ORD 기록
ord-e53a0caaff0c4ef5be0737b804b54553
출처 데이터셋
uspto-grants-2009_09
DOI
10.6084/m9.figshare.5104873.v1
특허 번호
US07595312B2

반응 노트

불러오는 중…

이 페이지에서참가 물질실험 절차출처 및 근거반응 노트